Ledger.Open graph →
SEC Form D · filed February 6, 2018

GT Biopharma, Inc

Offering
$7.1M
Sold
$7.1M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Washington, Washington, D.C.
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (8)

Kathleen J. Clarence-Smith · Washington, Washington, D.C.Exec · DirectorAnthony J. Cataldo · Washington, Washington, D.C.DirectorGeoffrey B. Davis · Washington, Washington, D.C.DirectorSteven Weldon · Las Vegas, NVExec · DirectorGeoffrey B. Davis · Washington, Washington, D.C.DirectorKathleen J. Clarence-Smith · Washington, Washington, D.C.Exec · DirectorAnthony J. Cataldo · Washington, Washington, D.C.DirectorSteven Weldon · Washington, Washington, D.C.Exec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗